EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma

Nikolaos G Papadopoulos iD, Stanley J Szefler, Leonard B Bacharier, Jorge F Maspero iD, Christian Domingo, Alessandro Fiocchi iD, Jason K Lee, Nadia Daizadeh, David J Lederer, Megan Hardin, Rebecca Gall, Michel Djandji und 4 weitere

Allergy · 2023-08 · 78 (8) · 2157-2167

DOI: 10.1111/all.15743 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 25.05.2023. Verfasst von Nikolaos G Papadopoulos und 15 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, The 2nd Pediatric Clinic, University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL‐4/IL‐13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated in patients aged 6–11 years with type 2 asthma with or without evidence of allergic asthma (baseline serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen‐specific IgE ≥0.35kU/L).

Methods

Annualized severe exacerbation rates (AER) and changes in pre‐bronchodilator (Pre‐BD) forced expiratory volume in one second (FEV 1 ), percent‐predicted pre‐BD FEV 1 (ppFEV 1 ), and Asthma Control Score (ACQ)‐7 were assessed during the treatment period.

Results

350 children (261 with and 89 without evidence of allergic asthma) were included. Dupilumab versus placebo significantly reduced AER in patients with (0.24 vs. 0.62, relative risk reduction [RRR]: 62% [95% CI, 39–76], P < .0001) and without (0.39 vs. 0.80, RRR: 51% [95% CI, 0–76], P < .05) evidence of allergic asthma. Significant improvements in ppFEV 1 , pre‐bronchodilator FEV 1 , and ACQ‐7 scores were observed in dupilumab versus placebo throughout the treatment period in patients with evidence of allergic asthma. In patients without evidence of allergic asthma, numerical improvements in pre‐bronchodilator FEV 1 and asthma control were observed by Week 52.

Conclusion

Dupilumab versus placebo reduced asthma exacerbations in children with type 2 asthma irrespective of evidence of allergic asthma; similar trends were observed in changes in lung function. Significant improvement in asthma control was observed in patients with evidence of allergic asthma, but not in those without.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaHumansMaleFemaleChildDisease ProgressionPlacebosForced Expiratory VolumeLung

Stichwörter der Autor:innen

allergicasthmaexacerbationpercentage predicted FEV1, dupilumab

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedPlacebos

Autor:innen und Institutionen

  • Allergy Department, The 2nd Pediatric Clinic, University of Athens, Athens, Greece.
  • Department of Pediatrics, The Breathing Institute, The University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.
  • Division of Allergy, Immunology and Pulmonary Medicine, The Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Allergy and Respiratory Medicine, The Fundación CIDEA, Buenos Aires, Argentina.
  • Pulmonary Service, The Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain.
  • Department of Allergy, The Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

ORCID-Profile: Nikolaos G Papadopoulos, Jorge F Maspero, Alessandro Fiocchi

Förderung

  • Sanofi

Zitieren

APA

Papadopoulos, N. G., Szefler, S. J., Bacharier, L. B., Maspero, J. F., Domingo, C., Fiocchi, A., Lee, J. K., Daizadeh, N., Lederer, D. J., Hardin, M., Gall, R., Djandji, M., Siddiqui, S., Jacob-Nara, J. A., Deniz, Y., & Rowe, P. J. (2023). Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma. Allergy, 78(8), 2157-2167. https://doi.org/10.1111/all.15743

Vancouver

Papadopoulos NG, Szefler SJ, Bacharier LB, Maspero JF, Domingo C, Fiocchi A, et al. Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023;78(8):2157-2167. doi:10.1111/all.15743

BibTeX
@article{Papadopoulos2023,
  author = {Papadopoulos, Nikolaos G and Szefler, Stanley J and Bacharier, Leonard B and Maspero, Jorge F and Domingo, Christian and Fiocchi, Alessandro and Lee, Jason K and Daizadeh, Nadia and Lederer, David J and Hardin, Megan and Gall, Rebecca and Djandji, Michel and Siddiqui, Shahid and Jacob-Nara, Juby A and Deniz, Yamo and Rowe, Paul J},
  title = {Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma},
  journal = {Allergy},
  year = {2023},
  volume = {78},
  number = {8},
  pages = {2157--2167},
  doi = {10.1111/all.15743}
}
Kostenlos starten →